Heather McArthur, MD, MPH

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Dr. McArthur discusses the latest results of immunotherapy trials in the treatment of triple-negative breast cancer.

Brain metastasis remains a relatively common and particularly devastating complication of breast cancer and has proven a particularly challenging area for therapeutic innovation.